| Literature DB >> 33066416 |
Mudassar Mohiuddin1,2, Zahid Iqbal3, Abubakar Siddique4, Shenquan Liao1, Muhammad Khalid Farooq Salamat5, Nanshan Qi1, Ayesha Mohiud Din6, Mingfei Sun1.
Abstract
Clostridium perfringens poses a serious threat to small ruminants by causing moderate to severe enterotoxaemia. Due to its ability to produce a wide arsenal of toxins, it is ranked among the most prevalent and important pathogens in livestock. This study focused on the molecular characterization of different Clostridium perfringens types along with their antimicrobial resistance profile. An overall higher prevalence of C. perfringens (46.1%) was detected based on mPCR among sheep and goats (healthy and diseased) in the Punjab province, Pakistan. The majority of the isolates were characterized as type A (82%), followed by type D (18%). Among the isolates from diseased sheep and goats, 27% were positive for cpa, 49% for cpa and cpb2, 9% for cpa and etx, 15% for cpa, cpb2 and etx. In the case of isolates from healthy sheep and goats, 59% were positive for cpa, 34% for cpb2 and cpa, 4% for cpa and etx, and 3% for cpa, cpb2 and etx. The prevalence of the beta2 toxin gene in the diseased sheep and goat population was 64% as compared to 37% in healthy animals. All 184 isolates (100%) were sensitive to rifampin and ceftiofur; the majority (57%) was sensitive to teicoplanin, chloramphenicol, amoxicillin, linezolid and enrofloxacin. A lower proportion of isolates (43%) were sensitive to ciprofloxacin and only 14% were susceptible to erythromycin. The findings of this study highlight the higher prevalence of C. perfringens in small ruminants and indicate that detailed pathogenesis studies are necessary to understand the explicit role of various toxins in causing enteric infections in sheep and goats including how they might be exploited to develop vaccines against these diseases.Entities:
Keywords: C. perfringens; antimicrobial susceptibility; goats; multiplex PCR; sheep; toxinotyping
Mesh:
Substances:
Year: 2020 PMID: 33066416 PMCID: PMC7602233 DOI: 10.3390/toxins12100657
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Carbohydrate fermentation reactions of C. perfringens field isolates. These isolates were placed in groups on the basis of variation in the fermentation reactions of sugars by different isolates.
| Groups | Carbohydrate Fermentation | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Glucose | Mannitol | Lactose | Sucrose | Maltose | Salicin | Xylose | Arabinose | Glycerol | Cellobiose | Mannose | Melezitose | Raffinose | Sorbitol | Rhamnose | Trehalose |
| Group I isolates | + | − | + | + | + | − | − | − | + | − | + | − | − | − | − | + |
| Group II isolates | + | − | + | + | + | − | − | − | − | − | + | − | − | − | − | + |
| Group III isolates | + | − | + | + | + | − | − | − | − | − | + | − | + | − | − | + |
| Group IV isolates | + | − | + | + | + | − | − | − | + | − | + | − | + | − | − | + |
| Esculin positive isolates (2%) | + | − | + | + | + | − | − | − | + | − | + | − | − | − | − | + |
| Indole positive isolate (<1%) | + | − | + | + | + | − | − | − | + | − | + | − | − | − | − | + |
+: indicates sugar fermentation and −: no sugar fermentation.
Biochemical characteristics of C. Perfringens isolates.
| Microorganism | Egg Yolk Agar | Biochemical Tests | |||||
|---|---|---|---|---|---|---|---|
|
| Lecithinase Production | Lipase Production | Gelatin Hydrolysis | Indole Production | Urease Test | Esculin Hydrolysis | Catalase Test |
| Group I, II, III, IV isolates | + | − | + | − | − | − | − |
| Esculin positive isolates (2%) | + | − | + | − | − | + | − |
| Indole positive isolate (<1%) | + | − | + | + | − | − | − |
+: positive reaction and −: negative reaction.
Figure 1Agarose gel electrophoresis of PCR products. Lanes: 1, negative control (no template DNA); 2, 1000 bp ladder; 3,4,8, C. perfringens isolate (genotype A, β2); 5,10, C. perfringens isolate (genotype A); 6, C. perfringens isolate (genotype D); 7,9, C. perfringens isolate (genotype D, β2); 11, Positive control.
Multiplex PCR results for the C. perfringens isolates (sheep and goat).
| S. No. | Toxin Gene of | Positive Cases | Total Fecal Samples Collected | Animal | |
|---|---|---|---|---|---|
| 1. |
| A | 65 (Diseased 42 + Healthy 23) | 148 | Goat |
| Aβ2 | |||||
| D | |||||
| D β2 | |||||
| 2. |
| A | 119 (Diseased 76 + Healthy 43) | 251 | Sheep |
| Aβ2 | |||||
| D | |||||
| D β2 |
Multiplex PCR results for the C. perfringens isolates (healthy and diseased).
| Positive Gene(s) | Isolate Population | |
|---|---|---|
| Healthy (n = 68) | Diseased (n = 116) | |
| 40 (59%) | 31 (27%) | |
| 23 (34%) | 57 (49%) | |
| 3 (4%) | 11 (9%) | |
| 2 (3%) | 17 (15%) | |
* significantly different values in a row (p < 0.05).
Figure 2Antibiotic susceptibility testing of Clostridium perfringens against different drugs.
Antibiotic susceptibility testing of Clostridium perfringens against different antibiotics.
| Antibiotics | Number of Strains of | |||
|---|---|---|---|---|
| Significant Susceptibility | Good Susceptibility | Moderate Susceptibility | Resistant | |
| Tetracycline (30 µg) | 26/184(14%) | 00 | 26/184(14%) | 132/184(72%) |
| Teicoplanin (30 µg) | 105/184(57%) | 53/184(29%) | 26/184(14%) | 00 |
| Enrofloxacin (5 µg) | 105/184(57%) | 79/184(43%) | 00 | 00 |
| Chloramphenicol (30 µg) | 105/184(57%) | 26/184(14%) | 53/184(29%) | 00 |
| Rifampin (5 µg) | 184/184(100%) | 00 | 00 | 00 |
| Amoxicillin (10 µg) | 105/184(57%) | 79/184(43%) | 00 | 00 |
| Penicillin G (10 µg) | 184/184(100%) | 00 | 00 | 00 |
| Ceftiofur (30 µg) | 184/184(100%) | 00 | 00 | 00 |
| Ciprofloxacin (5 µg) | 79/184(43%) | 53/184(29%) | 52/184(28%) | 00 |
| Erythromycin (15 µg) | 26/184(14%) | 132/184(72%) | 26/184(14%) | 00 |
| Norfloxacin (10 µg) | 00 | 00 | 184/184(100%) | 00 |
| Linezolid (30 µg) | 105/184(57%) | 26/184(14%) | 53/184(29%) | 00 |
| Neomycin (10 µg) | 00 | 00 | 00 | 184/184(100%) |
Oligonucleotide primers for multiplex PCR detection of C. perfringens toxin genes.
| Toxin Gene | Primers | Primer Sequence (5′–3′) | Product Size (bp) |
|---|---|---|---|
| CPA F | GCTAATGTTACTGCCGTTGA | 324 bp | |
| CPA R | CCTCTGATACATCGTGTAAG | ||
| CPB F | GCGAATATGCTGAATCATCTA | 195 bp | |
| CPB R | GCAGGAACATTAGTATATCTTC | ||
| CPB2 F | AAATATGATCCTAACCAACAA | 548 bp | |
| CPB2 R | CCAAATACTCTAATCGATGC | ||
| ETX F | TGGGAACTTCGATACAAGCA | 376 bp | |
| ETX R | AACTGCACTATAATTTCCTTTTCC | ||
| IA F | AATGGTCCTTTAAATAATCC | 272 bp | |
| IA R | TTAGCAAATGCACTCATATT | ||
| CPE F | TTCAGTTGGATTTACTTCTG | 485 bp | |
| CPE R | TGTCCAGTAGCTGTAATTGT |
Inhibition Criteria for C. perfringens isolates.
| Significant Level | Growth Inhibition |
|---|---|
| Resistant | ≤40% inhibition |
| Moderate Sensitivity | 40–60% inhibition |
| Good Susceptibility | 60–70% inhibition |
| Significant Susceptibility | 70% and above |